All In Biotech

Drug Trial Radar · NCT07851025

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Non-HRD Positive Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

950

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Jun 28, 2030

Study completion Aug 29, 2033

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

  • Torvutatug samrotecanDrug

    Antibody drug conjugate

  • BevacizumabDrug

    Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: up to approximately 5 years

Locations

220 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Tamarac, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Baton Rouge, Louisiana · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Billings, Montana · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Capital Federal, Argentina · Not yet recruiting

  • Research Site

    Ciudad de Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Ciudad de Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Córdoba, Argentina · Not yet recruiting

  • Research Site

    Córdoba, Argentina · Not yet recruiting

  • Research Site

    Córdoba, Argentina · Not yet recruiting

  • Research Site

    Rosario, Argentina · Not yet recruiting

  • Research Site

    Salta, Argentina · Not yet recruiting

  • Research Site

    Santa Fe, Argentina · Not yet recruiting

  • Research Site

    Viedma, Argentina · Not yet recruiting

  • Research Site

    Auchenflower, Australia · Recruiting

  • Research Site

    Benowa, Australia · Not yet recruiting

  • Research Site

    Hobart, Australia · Not yet recruiting

  • Research Site

    Kingswood, Australia · Not yet recruiting

  • Research Site

    Nedlands, Australia · Not yet recruiting

  • Research Site

    Port Macquarie, Australia · Not yet recruiting

  • Research Site

    Randwick, Australia · Not yet recruiting

  • Research Site

    Richmond, Australia · Not yet recruiting

  • Research Site

    Toorak Gardens, Australia · Not yet recruiting

  • Research Site

    Wollongong, Australia · Not yet recruiting

  • Research Site

    Woodville, Australia · Not yet recruiting

  • Research Site

    Fortaleza, Brazil · Not yet recruiting

  • Research Site

    Itajaí, Brazil · Not yet recruiting

  • Research Site

    Jaú, Brazil · Not yet recruiting

  • Research Site

    Natal, Brazil · Not yet recruiting

  • Research Site

    Porto Alegre, Brazil · Not yet recruiting

  • Research Site

    Rio de Janeiro, Brazil · Not yet recruiting

  • Research Site

    Salvador, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Dobrich, Bulgaria · Not yet recruiting

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.